Feature|Videos|June 25, 2025
Navigating Regulatory Barriers within Market Access
A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based endpoints to ensure successful access, pricing, and long-term market viability—especially in a more complex, globally integrated reimbursement landscape.
Advertisement
Episodes in this series
As international price referencing tightens and payer expectations rise, companies face a shrinking margin for error. The panel explores how clinical trial design and early payer engagement are key to meeting both regulatory and reimbursement demands across global markets. With real-world evidence (RWE) from markets like Korea and Japan in hand, forward-thinking strategies can prove valuable.
Key discussion topics include:
- Navigating international price referencing and fragmented regulatory standards.
- Why payer engagement should begin as early as clinical trial design.
- RWE as a tool for value messaging in global markets.
- The diminishing threat of generics for advanced therapies like cell therapy.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
4
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
5
